Clinical trial · Interventional
The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer
NCT00122720CI-TRIAL-00000364completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is investigating whether randomization to perioperative darbepoetin alfa treatment improves the rehabilitation following surgery for colonic and rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Darbepoetin Alfa | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The functional capacity measured by postoperative fatigue, work capacity, balance, and quality of life
Secondary outcomes (5)
- measure
- Muscular strength
- measure
- Weight
- measure
- Body composition
- measure
- Blood transfusion
- measure
- Postoperative complications
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Planned colonic and rectal surgery because of presumed cancer disease in the colon and rectum Exclusion Criteria: * Psychiatric disease or dementia * Diseases, that renders participation in the study impossible * Thromboembolic disease within the last three months * Dysregulated hypertension (systolic blood pressure\>175 mmHg and/or diastolic blood pressure\>105 mmHg) * Other diseases or causes that will contraindicate treatment with Darbepoetin Alfa * Other diseases or causes that will contraindicate further treatment with Darbepoetin Alfa * Patients that preoperatively and/or four days postoperatively have a hemoglobin concentration \> 14 g/dl * Former cancer disease * Disseminated cancer disease * Rectal cancer stage T4
References
Publications (0)
Data not yet available
No reference posted for this study.